AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04132115
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
Trial: NCT04132115
Drug: Fluconazol
RxNorm normalized name: Fluconazol
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
Trial: NCT04132115
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
Trial: NCT04132115
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
Trial: NCT01634685
Drug: Bavituximab
RxNorm normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
Trial: NCT04200833
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subcutaneous injection
Trial: NCT04224584
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
Trial: NCT02508870
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive atezolizumab as per the schedule described in individual cohort.
Trial: NCT02508870
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive azacitidine as per the schedule described in individual cohort.
Trial: NCT04341883
Drug: anti-PD-1+Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody
Trial: NCT01020825
Drug: ASCs
RxNorm normalized name: ASC-618
DrugBank: ASC-618 (DB18423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
Trial: NCT01020825
Drug: Fibrin glue
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After curettage, the fistulous tract was sealed with fibrin glue.
Trial: NCT01020825
Drug: ASCs
RxNorm normalized name: ASC-618
DrugBank: ASC-618 (DB18423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
Trial: NCT02108639
Drug: BMS-791325
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01951209
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550mg orally twice daily for 12 weeks
Trial: NCT04464369
Drug: itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
Trial: NCT02501863
Drug: Femoral nerve block with ropivacaine+fentanyl
RxNorm normalized name: fentanyl / ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
Trial: NCT02501863
Drug: Femoral nerve block with ropivacaine
RxNorm normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
Trial: NCT02622321
Drug: Emicizumab
RxNorm normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
Trial: NCT01851850
Drug: Opicapone
RxNorm normalized name: opicapone
DrugBank: Opicapone (DB11632)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg or 50mg once per day
Trial: NCT02622321
Drug: rFVIIa
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive rFVIIa.
Trial: NCT02622321
Drug: aPCC
RxNorm normalized name: APCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive aPCC.
Trial: NCT00118963
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets of 500 mg; 1000 mg two times daily.
Trial: NCT00118963
Drug: Insulin BIAsp30 (Novolog 70/30)
RxNorm normalized name: insulin aspart protamine, human
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
Trial: NCT00118963
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 1 mg; Dosage: 2 mg three times daily.
Trial: NCT00118963
Drug: Placebo-Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets corresponding to 500 mg; two tablets two times daily.
Trial: NCT00118963
Drug: Placebo-Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet corresponding to 1 mg; two tablets three times daily.
Trial: NCT00857870
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose.
Trial: NCT06298123
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after hepatic resection surgery were analysed by retrospectively collecting patient data from the Centre for Liver Surgery, Tongji Hospital, during the period of February 2019 to February 2023, and comprehensively evaluating the patients' demographic characteristics, oncological parameters, surgical details, and response to immunotherapy, and establishing a prognostic model based on these factors.
Trial: NCT00857870
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
Trial: NCT00109512
Drug: NBI-56418 (GnRH antagonist)
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02451696
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
Trial: NCT03891095
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasally administrated
Trial: NCT03891095
Drug: L-DOPA
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: orally administered
Trial: NCT00967148
Drug: Tinzaparin
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
Trial: NCT03348527
Drug: 2-Hydroxyflutamide Depot
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
Trial: NCT04323527
Drug: Chloroquine diphosphate
RxNorm normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
Trial: NCT02364258
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
Trial: NCT00397254
Drug: rizatriptan
RxNorm normalized name: Rizatriptan
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg ODT 27 tablets
Trial: NCT00397254
Drug: rizatriptan
RxNorm normalized name: Rizatriptan
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg ODT 9 tablets
Trial: NCT02024230
Drug: Rivaroxaban or Warfarin
RxNorm normalized name: Rivaroxaban
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
Trial: NCT00797472
Drug: ABVD
RxNorm normalized name: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
Trial: NCT03158376
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00232687
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
Trial: NCT00232687
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
Trial: NCT00766220
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions.
Trial: NCT00766220
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
Trial: NCT03780283
Drug: Anlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
Trial: NCT02161562
Drug: omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150mg omalizumab via sub-cutaneous injection once every 4 weeks
Trial: NCT02161562
Drug: omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300mg omalizumab via sub-cutaneous injection once every 4 weeks
Trial: NCT00049088
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03232450
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 81 mg enteric coated aspirin
Trial: NCT01519830
Drug: Iron carboxymaltose (Ferinject)
RxNorm normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous iron
Trial: NCT02705573
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
Trial: NCT02019069
Drug: liposomal cytarabine-daunorubicin CPX-351
RxNorm normalized name: cytarabine / daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03639389
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
Trial: NCT01877564
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02991196
Drug: DS-8273a + nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
Trial: NCT02959879
Drug: FOLFOX neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
Trial: NCT02959879
Drug: FOLFIRINOX neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
Trial: NCT03415867
Drug: Glasdegib
RxNorm normalized name: Glasdegib
DrugBank: Glasdegib (DB11978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
Trial: NCT02182596
Drug: Mylotarg
RxNorm normalized name: Mylotarg
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose level study
Trial: NCT00042835
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00042835
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00042835
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00042835
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00042835
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00042835
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02827097
Drug: denogan and rectus sheath block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of denogan and rectus sheath block with 0.375% ropivacaine
Trial: NCT04146805
Drug: BLD-0409
RxNorm normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Trial: NCT04425031
Drug: Low oxygenation target
RxNorm normalized name: low-density polyethylene
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
Trial: NCT04425031
Drug: High oxygenation target
RxNorm normalized name: high-density polyethylene
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
Trial: NCT00820885
Drug: teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
Trial: NCT00820885
Drug: teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
Trial: NCT00820885
Drug: tedguglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
Trial: NCT02906059
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01341951
Drug: Granulocyte colony stimulating factor
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 I.U twice daily for 5 days
Trial: NCT03701451
Drug: Demethylated drug decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
Trial: NCT00623077
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
Trial: NCT00623077
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
Trial: NCT00623077
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
Trial: NCT00623077
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
Trial: NCT00623077
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.